The DOI matches its Crossref record.
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Open accessAbstract
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post marketing surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Optimal treatment for recurrent/metastatic head and neck cancer
Vermorken, J. B., & Specenier, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq453 · Cited by 383
Marketed therapeutic antibodies compendium
Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.19931 · Cited by 368
Lee, J. Y., Sun, J.-M., Lim, S. H., Kim, H. S., Yoo, K. H., Jung, K. S., Song, H.-N., Ku, B. M., Koh, J., Bae, Y.-H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1653 · Cited by 36
“Fewer side effects of nimotuzumab comparedwithother anti-EGFRmAbsmaybe attributed to unique binding affinity in the range of 10 8 to 10 9 mol/L to maximize tumor cell targeting while minimizing normal cell toxicity (37, 38).”
Background
Metadata
- Authors
- Ramakrishnan, M. S., Eswaraiah, A., Crombet, T., Piedra, P., Saurez, G., Iyer, H., & Arvind, A. S.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 1
- Issue
- 1
- Pages
- 41-48
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2060875961
- Cited by
- 246
- References
- 0
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. https://app.cochat.ai/papers/10.4161/mabs.1.1.7509
- The paper
- Ramakrishnan, M. S., Eswaraiah, A., Crombet, T., Piedra, P., Saurez, G., Iyer, H., & Arvind, A. S. (2009). Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. https://doi.org/10.4161/mabs.1.1.7509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.